FAST Company


Epilepsy affects 70M people worldwide including 3.4M people in the US with costs > $15B USD, $1B in EEG costs alone.  Detecting and responding to seizures is critical to managing epilepsy.  However, > 50% of seizures are unreported because they are difficult to detect and/or not remembered by the person with epilepsy.  Eysz is a software-based digital therapeutic built on our patented algorithm that analyzes passive eye movement data to identify seizures, track side effects, and responds to medications in real-time. Eysz will empower neurologists, pharmaceutical researchers and neuromodulation companies with accurate data and address a significant unmet clinical need for timely therapeutic interventions, and assist in the development of new treatments for epilepsy.